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ABSTRACT Background: N-acetyl-glucosaminidase (NAG) is a potential marker of 
genotoxicity. We retrospectively analyzed plasma NAG and clinico-pathologic features in 
advanced gastrointestinal adenocarcinoma patients. Methods: Plasma from 118 patients and 
51 healthy volunteers was analyzed for associations between NAG levels and age, disease 
presence, stage, treatment responses and survival. Results: Pretreatment NAG correlated 
with age but was independently increased in metastatic versus locally advanced disease, 
particularly in gastric/esophageal patients. NAG was also associated with reduced overall 
survival. In subgroup analysis, increased NAG activity between day 1 and 2 of chemotherapy 
cycle 1 correlated with treatment response. Conclusion: We demonstrated that NAG 
correlates with gastrointestinal cancer outcomes. Further studies are required to determine 
if plasma markers of genotoxicity can be useful for disease monitoring.
Background
Biological age is a risk factor in many cancers and the molecular factors underpinning cellular aging 
including telomere dysfunction and DNA damage responses have been shown to be common features 
at early stages of carcinogenesis [1]. These molecular events have been investigated in tumor samples by 
approaches including fluorescence hybridization and immunohistochemistry [2–4] and are intrinsically 
involved in cell aging and cellular senescence, correlating with tumor initiation of gastrointestinal 
tumors, such as adenocarcinoma of the stomach and colon [5]. There is considerable current interest 
in clinical application of markers of cellular senescence in cancer [6,7]. However, the ‘senectome’ is 
poorly defined and therefore there is a need to define the most appropriate markers for use in differ-
ent settings. Furthermore, in clinical practice, there is a need for markers that are easy to measure in 
patient material and that are accessible to repeat sampling, ideally in blood for treatment monitoring.
Recently, we described the identification of secreted proteins including the Chitinase enzyme 
N-acetyl-glucosaminidase (NAG) that are elevated in aging human fibroblasts preceding the onset of 
senescence and in response to DNA damage. NAG can be detected in human blood and increases with 
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human aging [8]. In this study, we investigated 
its association with gastrointestinal adenocarci-
noma. We measured plasma NAG levels in 118 
patients and 51 healthy volunteers to examine 
associations with objective treatment response 
to chemotherapy and with overall survival in 
addition to other clinico-pathologic features.
●● Patients & methods
The recruitment criteria and sampling methods 
used in the current study were previously reported 
in [9]. The study was approved by the West 
Glasgow Hospitals Research Ethics Committee, 
and all patients gave written informed consent 
before undertaking any study-related procedures. 
The study was designed to investigate potential 
biomarkers of response to palliative fluoropyrimi-
dine-based chemotherapy in advanced gastroin-
testinal cancer patients. Eligible patients were 
those attending for chemotherapy treatment at a 
single institution (the Beatson West of Scotland 
Cancer Center, Glasgow, UK) with histologically 
or cytologically confirmed, locally advanced or 
metastatic gastrointestinal adenocarcinoma who 
were due to start systemic anticancer therapy, 
with either adenocarcinoma of the colon or rec-
tum receiving fluoropyrimidine-based therapy or 
adenocarcinoma of the oesophagus or stomach 
receiving chemotherapy with a regimen contain-
ing a fluoropyrimidine and a platinum analogue. 
Additional inclusion criteria were age ≥18 years, 
ability to comply with study procedures and life 
expectancy ≥3 months. Patients who had systemic 
anticancer therapy or radiotherapy within the 
previous 6 weeks were excluded, as were women 
who were pregnant or lactating.
Plasma samples were obtained from 118 
patients with gastrointestinal cancer who were 
treated at the Beatson West of Scotland Cancer 
Center, and from 51 healthy volunteers (con-
trol group). The volunteers in this retrospective 
analysis were not age-matched. Chemotherapy 
was administered according to local protocols. 
20 ml of blood were collected before starting 
chemotherapy (baseline) and before admin-
istration of each subsequent course of chemo-
therapy [9]. Disease response was assessed 
clinically and by computed tomography scans 
performed before commencing chemotherapy 
and at regular intervals during treatment (after 
cycles 3 and 6 for patients with gastric or esopha-
geal cancer and patients with colorectal cancer 
receiving capecitabine, and after cycles 6 and 
12 in patients with colorectal cancer receiving 
infusional 5-f lourouracil-based regimens). 
Disease response, as defined by the RECIST 
criteria [10], was determined from the radiology 
reports for individual patients. Epithelial toxicity 
experienced by patients during chemotherapy 
was assessed by review of an individual patient’s 
case records, but detailed toxicity assessments 
were not prospectively recorded in this study [9].
Enzyme activity of NAG was determined 
with the Chitinase assay kit on baseline (pre-
treatment) samples (CS1030; Sigma, MO, USA) 
according to the manufacturer’s instructions and 
our previous report [8]. 2 μl of plasma was used 
per reaction. A control sample was included in 
quadruplicate on each assay plate to control for 
intra- and inter-plate variance. Plasma levels in 
patients versus volunteers, in locally advanced 
versus metastatic disease, and relation between 
NAG levels and patient response were analyzed 
by Mann-Whitney U-test and logistic regression. 
Correlation to age was determined by Spearman 
rank correlation test. Association between base-
line (pretreatment) levels and primary disease 
site was assessed by Kruskal–Wallis test. To test 
for a correlation between baseline levels and 
overall survival, Cox regression analysis was 
performed, with NAG examined continuously.
Results
●● NAG positively correlates with age
We have previously shown that NAG is increased 
in unaffected elderly individuals by comparison 
with healthy young individuals [8,11]. To deter-
mine whether this association held in the cur-
rent patient group, we compared baseline lev-
els within the patient group using Spearman’s 
rank correlation test. Patient characteristics are 
given in Table 1. Median age was 68.5 years. 
As shown in Figure 1A, positive correlation was 
observed (r = 0.334). Gender was not associ-
ated with baseline levels in the patient group by 
Mann–Whitney test (Figure 1B, NAG: female 
29.81 U/ml, male 33.44 U/mLl, p = 0.151).
We next analyzed baseline (pretreatment) 
levels of NAG in plasma samples of the patient 
group (colorectal, gastric, and esophageal can-
cer patients) compared with healthy volunteers. 
Figure 1C shows these results. Median activity 
in the patient group was higher at 32.1 U/ml 
compared with 23.65 U/ml in the control group 
(p < 0.001, Mann–Whitney test). However, in 
this retrospective study the volunteer group was 
not age-matched and was significantly younger 
(p < 0.001) than the patients (Table 1). Results of 
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a logistic regression analysis incorporating age 
and gender in addition to NAG levels (Table 2) 
showed that age was the only independent pre-
dictor of disease presence among these variables. 
Similar results were obtained when NAG activi-
ties were discretised to above- or below-median 
groups (Table 2).
Correspondingly, we asked whether age, gender 
and study status (patient/control) influence the 
discretized NAG categories (Table 3). In this analy-
sis, both age and gender are significantly associ-
ated with NAG activity, with the hazard ratio 
indicative of higher activities in males. However, 
study status was not significant. Spearman rank 
correlation including all individuals (patients and 
controls) gave a stronger correlation than patients 
only (Figure 1D, r = 0.527). NAG activity is thus 
strongly associated with age as previously observed, 
both in the patient cohort and in the entire group. 
Hence, age-matching will be required in future 
studies to address whether NAG is upregulated 
in patients relative to controls.
●● NAG is elevated in metastatic disease in 
patients with esophago-gastric cancer
We next assessed whether primary cancer site 
(gastric, colorectal, esophageal) is associated 
with baseline levels of NAG. No significant 
difference was detected by Kruskal–Wallis test 
(Figure 2A, p = 0.672). However, comparing 
locally advanced (24 patients) versus metastatic 
disease (94 patients), NAG was elevated in the 
metastatic group (Figure 2B, median 32.10 U/ml 
compared with 28.36 U/ml for locally advanced 
disease, p = 0.043 by Mann–Whitney).
In sub-group analysis of the disease stage 
according to tumor site, 58 patients had 
esophago-gastric adenocarcinoma (19 with 
locally advanced disease and 39 with meta-
static disease). NAG was again elevated in the 
Table 1. Patient and volunteer characteristics.
Characteristic Number
Patients: age  (years)
Median (68.5)  
Range (24–88) 118
Patients: gender
Female 49
Male 69
Patients: primary tumor site
Gastroesophageal 58
Colorectal 60
Patients: disease extent
Locally advanced 24
Metastatic 94
Patients: chemotherapy
Capecitabine 48
Capecitibine/oxaliplatin 6
FOLFIRI 1
5-flourouracil/folinic acid 5
ECF/ECX 51
Platinum/5-flourouracil 7
Patients: best response
Partial response 21
Stable disease 49
Disease progression 36
Non-evaluable 12
Healthy volunteers: age  (years)
Median (37.0)  
Range (22–55) 51
Healthy volunteers: gender
Female 26
Male 25
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Figure 1. N-acetyl-glucosaminidase correlates with age in plasma of gastrointestinal cancer 
patients and controls. (A) Baseline levels of NAG correlate with age in the patient group. Positive 
correlation was analyzed by Spearman’s rank correlation test. (B) No association between patient 
gender and NAG levels. P-values were calculated by Mann–Whitney test. (C) NAG is elevated 
in plasma of gastro-intestinal cancer patients. Baseline levels of NAG were measured in plasma 
of 118 gastrointestinal cancer patients and 51 healthy controls. P-values were calculated by 
Mann–Whitney test. (D) Stronger correlation of baseline NAG levels with age after inclusion of the 
healthy controls. Positive correlation was analyzed by Spearman’s rank correlation test. 
NAG: N-acetyl-glucosaminidase.
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Table 2. Logistic regression model of predictors of presence of disease.
Predictors of 
presence of 
disease
N  B  SE  p-value  Hazard ratio 
[Exp(B)] 
95% CI for Exp(B)
Lower Upper
NAG baseline 169 -0.046 
(0.007)
0.049 (0.81) 0.346 
(0.993)
0.955 (1.007) 0.868 
(0.206)
1.051 
(4.924)
Age 169 0.239 
(0.218)
0.044 
(0.038)
<0.001 
(<0.001)
1.270 (1.244) 1.165 
(1.156)
1.383 
(1.339)
Gender 169 -1.184 
(-1.004)
0.716 
(0.692)
0.098 
(0.147)
0.306 (0.366) 0.075 
(0.094)
1.245 
(1.423)
118 patients and 51 healthy controls were included in the analysis. Values are results obtained with NAG treated continuously or, in 
brackets, discretised to above- or below-median.  
B: Unstandardized regression coefficients; N: Number of individuals included in the analysis; NAG: N-acetyl-glucosaminidase; 
SE: Standard errors associated with the coefficients.
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Figure 2. N-acetyl-glucosaminidase activity is associated with disease progression in gastric/
esophageal cancer patients. (A) No association between baseline plasma levels of NAG and primary 
tumor site analyzed by Kruskal–Wallis test. (B) Elevated baseline plasma NAG levels in metastatic 
compared with locally advanced disease in the whole patient group, or (C) in a subgroup of 58 
patients with gastric or esophageal cancers. P-values were calculated by Mann–Whitney test. 
NAG: N-acetyl-glucosaminidase.
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metastatic group (Figure 2C) with median activ-
ity of 33.04 U/ml compared with 25.75 U/ml 
for locally advanced disease (p = 0.019). Hence, 
NAG activity associates with more advanced dis-
ease in esophago-gastric adenocarcinoma in the 
current cohort. The remaining 60 patients had 
colorectal cancer of which only five had locally 
advanced and 55 had metastatic disease. This 
number of patients with locally advanced dis-
ease is too small to allow an adequately powered 
comparison. To confirm that NAG association 
with metastatic disease is independent of other 
variables, we again performed logistic regression 
analysis, incorporating primary site, age, gen-
der and NAG baseline activity (Table 4). In this 
analysis, primary site, NAG baseline and patient 
age were all statistically significant. However, 
because the limited number of locally advanced 
colorectal cancer patients will influence the 
contribution of primary site in this analysis, we 
also tested the other variables without includ-
ing primary site (Table 4, in parentheses). The 
results were similar for NAG activity in both 
analyses. However, NAG activity was the only 
significant predictor variable when primary site 
was excluded. Hence, pretreatment NAG activ-
ity is an age-independent predictor of metastatic 
disease in the current patient group.
●● Dynamic changes in NAG levels on 
chemotherapy initiation associate with 
treatment response
To determine whether there is correlation 
between baseline NAG levels and objective tumor 
response, response rates were determined both for 
the entire patient group and for the individual 
tumor sites (partial response or stable disease 
versus progressive disease). No significant asso-
ciation between response rate and baseline lev-
els was observed in the whole cohort (PR+SD, 
n = 70; PD, n = 36; p = 0.219 by Mann–Whitney, 
Figure 3A). Similarly, no association between base-
line levels and response rate was found by analysis 
of individual tumor sites (Figure 3B). However, in 
a subgroup of 24 esophago-gastric patients from 
whom plasma samples had been taken on both 
Table 3. Logistic regression model of predictors of N-acetyl-glucosaminidase activity in 118 
patients and 51 controls.
Predictors of 
NAG activity
N  B  SE  p-value  Hazard ratio 
[Exp(B)] 
95.0% CI for Exp(B)
Lower Upper
Age 169 0.087 0.021 <0.001 1.090 1.046 1.136
Gender 169 -0.827 0.383 0.031 0.437 0.207 0.926
Patient/control 169 -0.108 0.701 0.878 0.898 0.227 3.546
B: Unstandardized regression coefficients; N: Number of individuals included in the analysis; NAG: N-acetyl-glucosaminidase. 
SE: Standard errors associated with the coefficients.
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Figure 3. Dynamic changes in N-acetyl-glucosaminidase activity in early chemotherapy predict 
treatment responses. N-acetyl-glucosaminidase activity was assessed in the groups partial 
response plus stable disease versus progressive disease. (A) No association between baseline levels 
of NAG activity in the whole cohort and treatment responses. P-values were calculated by Mann–
Whitney test. (B) No association between baseline levels of NAG activity and treatment responses by 
primary site. P-values were calculated by Mann–Whitney test. (C) A subset of 28 patients had plasma 
samples taken on both treatment days 1 and 2 of chemotherapy cycle 1. Increased NAG activities 
were detected in the PR/SD group between the treatment days. P-values were calculated by Mann–
Whitney test. (D) No association between age and treatment response in the whole cohort. P-values 
were calculated by Mann–Whitney test. (E) No association between age and treatment response in 
the treatment day 1–2 subgroup. P-values were calculated by Mann–Whitney test. 
NAG: N-acetyl-glucosaminidase; PD: Progressive disease; PR: Partial response; SD: Stable disease. 
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Table 4. Logistic regression model of predictors of disease stage.
Predictors of 
disease stage
N  B  SE  p-value  Hazard ratio 
[Exp(B)] 
95.0% CI for Exp(B)
Lower Upper
Primary site 118 -1.967 (n/a) 0.594 (n/a) <0.001 
(n/a)
0.140 (n/a) 0.044 
(n/a)
0.448 
(n/a)
NAG baseline 118 0.083 (0.076) 0.032 
(0.032)
0.010 
(0.017)
1.087 (1.080) 1.020 
(1.014)
1.158 
(1.149)
Age 118 -0.060 
(-0.034)
0.029 
(0.024)
0.041 
(0.170)
0.942 (0.967) 0.890 
(0.922)
0.998 
(1.014)
Gender 118 0.455 (0.409) 0.533 
(0.490)
0.393 
(0.403)
1.576 (1.506) 0.555 
(0.576)
4.480 
(3.936)
Values are results obtained with or without (parentheses) inclusion of primary site in the model.  
B: Unstandardized regression coefficients; N: Number of individuals included in the analysis; n/a: Not applicable;  
NAG: N-acetyl-glucosaminidase; SE: Standard errors associated with the coefficients.
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day 1 and day 2 of treatment cycle 1, we found 
significant changes in NAG levels between sam-
ples, with the magnitude of change (day 2 levels 
– baseline) significantly greater in the responders 
(n = 16) than the non-responders (n = 8, Figure 3C, 
p = 0.006, Mann–Whitney test).
In particular, NAG activity is substantially 
increased on treatment day 2 in the stable dis-
ease/responding group, but the levels were com-
paratively unaffected in patients with progressive 
disease. No association between age and response 
was observed by Mann–Whitney analysis, either 
in the whole cohort (Figure 3D, p = 0.304) or in 
the subgroup sampled on both treatment days 
(Figure 3E, p = 0.256). Furthermore, in a logistic 
regression analysis incorporating age, sex and dis-
ease stage, NAG activity change remained the 
only significant independent predictor of response 
to therapy (Table 5). Hence, these results appear 
age-independent. Therefore, increased NAG 
activity shortly after initiation of chemotherapy 
appears to predict treatment response.
●● NAG levels significantly correlate with 
poor overall patient survival
Of 118 patients, 115 were dead and three alive 
at the time of analysis. In order to test for a cor-
relation between baseline levels and overall sur-
vival, Cox regression analysis was performed 
examining NAG baseline levels, age, gender and 
disease stage. Baseline NAG levels were the only 
significant predictor in this analysis (p = 0.033). 
Hence, baseline NAG levels correlate with over-
all survival (Table 6). In order to further examine 
the association between NAG levels and overall 
survival, the data were split according to quartiles 
and log rank test was performed on the survival 
distributions of the upper and lower quartiles 
(Figure 4A, p = 0.045). High pretreatment levels 
of NAG were associated with poor overall sur-
vival in the current cohort. Median survival for 
the quartile of patients with highest NAG activ-
ity (Q4) was 6.2 months compared with 12.3 
months for the quartile (Q1) of patients with low-
est NAG activity in plasma (Figure 4B, p = 0.016 
by Mann–Whitney). Spearman rank correlation 
analysis in all patients also revealed a significant 
negative correlation between NAG levels and 
survival time (Figure 4C; r = -0.228; p = 0.014). 
Hence, high plasma NAG levels were associated 
with lower survival times in these patients.
Discussion
NAG has previously been identified as a secreted 
marker of DNA damage that is upregulated prior 
to onset of cellular senescence and that associ-
ates with human aging and the evolution of age 
associated disease, such as Alzheimers’ disease 
[8,11,12]. Here, we report a study of the levels in 
plasma of patients with gastro-intestinal adeno-
carcinoma. It could not be determined in the 
current retrospective study whether NAG is 
increased in this patient group relative to healthy 
volunteers because age-matching was not per-
formed. Furthermore, the current study was ret-
rospective and it was unfortunately not possible 
to identify an age-matched subgroup from the 
volunteers of sufficient size to permit any robust 
statistical analysis from the available samples.
However, in line with our previous find-
ings, NAG activity strongly correlated with age 
both in the patient group and in all individu-
als. These results provide further evidence that 
plasma NAG is a marker of human organismal 
aging. This is the first time that age dependence 
of NAG activity has been demonstrated within 
a cancer patient population which is itself an 
important finding, but the observed age depend-
ence may also be a feature of other candidate 
markers of cellular senescence. Hence, future 
prospective studies designed to validate this or 
other senescence markers should incorporate 
age-matching not only of controls/patients but 
also, for example, of treatment arms.
Within the patient group, NAG was found 
to be elevated in metastatic disease both in the 
Table 5. Logistic regression model of predictors of treatment response.
Predictors of 
treatment 
response
N  B  SE  p-value  Hazard ratio 
[Exp(B)] 
95.0% CI for Exp(B)
Lower Upper
Age 24 0.065 0.060 0.279 1.067 0.949 1.201
NAG change 24 0.504 0.249 0.043 1.656 1.016 2.700
Gender 24 -0.506 1.111 0.649 0.603 0.068 5.326
Disease stage 24 0.968 1.256 0.441 2.634 0.225 30.863
B: Unstandardized regression coefficients; N: Number of individuals included in the analysis; NAG: N-acetyl-glucosaminidase; 
SE: Standard errors associated with the coefficients.
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Figure 4. High baseline N-acetyl-glucosaminidase activity associates with poor overall survival 
in advanced gastrointestinal adenocarcinoma. (A) Kaplan–Meier plot of overall survival in the 
upper (Q4, n = 30) and lower (Q1, n = 30) quartiles of NAG activity demonstrating that high activity 
corresponds with poor outcome. Results of the Cox regression analysis are given in Table 6. (B) Survival 
time distributions in the Q1 and Q4 groups. P-values were calculated by Mann–Whitney test. 
(C) Inverse correlation between NAG levels and survival time analyzed by Spearman rank correlation. 
NAG: N-acetyl-glucosaminidase.
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whole patient cohort and in the esophago-gastric 
subgroup. Levels did not associate with tumor 
primary site and no clear relation was found 
between baseline (pretreatment) levels and objec-
tive treatment response either in the entire cohort 
or in tumor-site subgroups. However, in a subset 
Table 6. Correlation of baseline N-acetyl-glucosaminidase levels and overall survival in Cox 
regression model.
Correlation with 
overall survival
N  B  SE  p-value  Hazard ratio 
[Exp(B)] 
95.0% CI for Exp(B)
Lower Upper
NAG baseline 118 0.024 0.011 0.033 1.024 1.002 1.047
Gender 118 -0.301 0.193 0.119 0.740 0.507 1.081
Disease stage 118 0.315 0.242 0.193 1.370 0.853 2.200
Age 118 -0.009 0.009 0.339 0.991 0.974 1.009
B: Unstandardized regression coefficients; N: Number of individuals included in the analysis; NAG: N-acetyl-glucosaminidase; 
SE: Standard errors associated with the coefficients.
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of patients from whom plasma was collected on 
both treatment day 1 and day 2, increases in activ-
ity following first treatment were associated with 
tumor response to therapy and NAG change was 
the only independent predictor in a logistic regres-
sion model incorporating age, gender and disease 
stage. Furthermore, baseline NAG levels were sig-
nificantly associated with poor outcome in this 
study (hazard ratio 1.024) in Cox regression analy-
sis incorporating age, gender and disease stage. 
These results may reflect the higher pretreatment 
expression observed in metastatic disease.
It will be of considerable interest to investigate 
dynamics of NAG plasma activity in response to 
therapy and as a possible predictor of outcome in 
future prospective studies. It is possible that this 
increase reflects an acute response to therapy given 
the relation between this marker and DNA dam-
age responses. High baseline levels in the non-
responders that were unaffected may be indicative 
of chronic DNA damage signaling in the tumor 
and resistance to therapy. This study was designed 
specifically to investigate potential biomarkers of 
response to palliative fluoropyrimidine-based 
chemotherapy and this is the first demonstra-
tion that cytotoxic therapies can affect plasma 
NAG in this group. It will therefore be of con-
siderable interest to investigate the potential for 
radiotherapy and other DNA-damaging chemo-
therapies to produce similar effects on NAG in 
future studies. Indeed, one possible application 
of plasma NAG is as a candidate marker of treat-
ment–induced cellular senescence. Since the cur-
rent study excluded patients treated with systemic 
therapy within 6 weeks of enrollment, we believe 
that potentially confounding effects of prior treat-
ment with other agents, which might affect NAG, 
should not affect our analysis and interpretation.
Substantial current interest in senescence 
induction as a potential therapeutic modality in 
cancer treatment implies a need for markers of 
senescence responses with utility in the clinical 
setting [7]. It is widely held that a robust senes-
cence signature will comprise several well-defined 
and easily assayed markers [6,13–15]. NAG activity 
may be a candidate since it has been linked with 
telomere dysfunction and is known to be upregu-
lated in presenescent cells [8]. In the current study 
it appears to have some prognostic significance, 
though future prospective studies in larger cohorts 
will be required to confirm these findings.
Telomere length, and in particular periph-
eral blood telomere length, has also been widely 
investigated as a cancer risk factor and shorter 
telomeres appear to correlate with increased risk 
in several cancer types [16]. Telomere shortening 
is also likely to be involved in tumor initiation of 
gastrointestinal tumors [17]. Some studies of this 
tumor group have shown a tendency for increased 
risk with detection of short telomeres in blood, 
although small effect sizes have led to a suggestion 
that larger trials would be appropriate [18]. It seems 
logical that combining telomere length with other 
candidate senescence markers may be an appropri-
ate measurement in future studies. However, use 
of a senescence signature as a monitoring tool in 
the clinical setting will also require changes in sig-
nal to be clearly correlated among diverse markers. 
In this respect, we found that increasing activity of 
NAG can be detected in response to a treatment 
cycle with fluoropyrimidine and the magnitude 
of elevation correlates with response to treatment.
Hence, greater understanding of the plasma 
dynamics of NAG (and other candidate markers 
of DNA damage and senescence) and their rela-
tion to treatment response may be of considerable 
importance. Correlating changes among markers 
will also be of interest. To address this, we have 
recently initiated two large prospective longitu-
dinal studies (UK Clinical Research Network 
trials 12434 and 12435), also in advanced gastro-
intestinal adenocarcinoma patients treated with 
fluoropyrimidine therapy. The objective of these 
studies is to measure the dynamics of a range of 
blood-based markers of aging, senescence and 
DNA damage. Results of these ongoing studies 
should help to clarify the significance of plasma 
biomarker dynamics in these patients.
Conclusion
Our study provides the first evidence that plasma 
NAG activity associates with gastrointestinal 
cancer outcomes and treatment responses, sup-
porting the concept that plasma markers of 
human aging and DNA damage may be clini-
cally useful for disease monitoring. Further pro-
spective studies will be needed to extend these 
results and to correlate NAG levels with other 
candidate senescence markers.
Future perspective
In order for the promise of stratified medicine to 
be fulfilled in cancer therapy a wide range of new 
biomarkers will be required, both to characterize 
disease and to sensitively monitor responses to 
therapy. Markers related to senescence, inflam-
mation and DNA damage are emerging as 
potentially important candidates in this respect 
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given the intrinsic involvement of these processes 
in cancer progression and therapeutic responses. 
However, there are many potential candidates 
for evaluation related to these processes and no 
single marker definitively points to senescence. 
Hence, it is likely that panels of biomarkers will 
be required in most settings to provide reliable 
prediction of complex disease processes.
Markers, such as NAG, which are detectable in 
blood and are thus amenable to repeat sampling 
will be extremely valuable in the longitudinal 
studies, such as UK Clinical Research Network 
trials 12434 and 12435, that will be required 
to understand how molecular dynamics corre-
late with outcomes in the therapeutic setting. 
However, validation of each candidate will still 
require their evaluation in prospectively designed 
and adequately powered studies. To accelerate 
this process, it will be necessary to establish net-
works of expertise involving strong collaboration 
among different clinical centers and research sites 
to bring together the skills required to facilitate 
complex trials involving multiple markers.
In the UK, the Experimental Cancer Medicine 
Center network and the Cancer Research UK 
Stratified Medicine Programme provide tem-
plates at the national scale, although interna-
tional networks should also be fostered. This new 
‘network approach’ to translational medicine has 
the potential to increase patient access to novel 
therapies, as well as speeding recruitment to tri-
als and increasing the rate of translation of new 
markers, which will ultimately provide the tools 
we require in order to better understand the het-
erogeneity of cancer within the individual and 
the population.
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EXECuTiVE SummARY
 ●  N-acetyl-glucosaminidase (NAG) is a candidate plasma marker of DNA damage and senescence.
 ●  Plasma NAG levels correlate with age in gastrointestinal cancer patients and in healthy individuals.
 ●  High pretreatment NAG levels were associated with metastatic disease independently of age in gastric/esophageal 
patients.
 ●  Altered NAG levels were detectable following the initiation of fluropyrimidine therapy and corresponded to treatment 
response.
 ●  High pretreatment NAG levels were independently associated with poor outcome.
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